The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Subscribe To Our Newsletter & Stay Updated